Floatz logo
Floatz Rating
B61/100
Confidence
Indicative
v0.2
Sponsor
Antalya Training and Research Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
Unknown
Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block in Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction - a Non-inferiority Trial
Unknown
Metabolomic Profiling of Erector Spinae Plane Block* for Breast Cancer Surgery
Completed
A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer
Terminated
Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction
Withdrawn
Post Mastectomy Pain Syndrome After Preoperative Stellate Ganglion Block for Breast Cancer Surgeries
Unknown
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
Completed
Liposomal Bupivacaine in Implant Based Breast Reconstruction
Terminated
Effect of Morphine, Tramadol, and Ketorolac on Postoperative Stress and Immune Responses
Unknown

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Breast Cancer

AssetSponsorPhaseRating
Nepenthe (this asset)Antalya Training and Research HospitalApprovedB · 61
DarolutamideVandana AbramsonP2BBB
PertuzumabSWOG Cancer Research NetworkP4BB
PalbociclibHoffmann-La RocheP4BB
Trastuzumab DuocarmazineByondis B.V.P3BB
GoserelinTerSera Therapeutics LLCP4BB
RibociclibNational Cancer Institute (NCI)P4BB
OxaliplatinBeijing Biostar Pharmaceuticals Co., Ltd.P4BB
Eribulin MonomethanesulfonateHenan Cancer HospitalP4BB

+42 more in the Breast Cancer cohort

Other indications for Nepenthe

IndicationSponsorPhaseRating
Cancer Of Unknown Primary SiteP4BBB · 75
Chronic Pain SyndromeP4BBB · 74
Post-Operative Pain, Non-Human AnimalP4BBB · 73

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Nepenthe in Breast Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nepenthe-breast-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →